Researchers presented two radiation oncology trials that aimed to improve local tumor control in NSCLC patients. One trial found no significant difference in 2-year local-regional tumor progression-free rates between adaptive and standard radiation therapy arms, while another study demonstrated excellent local control rates with dose e...
Researchers found that combining ipilimumab with pembrolizumab did not significantly improve overall survival or progression-free survival for patients with NSCLC. The combination was also associated with greater treatment-related adverse events.
In the phase II CodeBreak 100 trial, sotorasib demonstrated a confirmed response rate of 32.2%, a median duration of response of 10.9 months, and a median progression-free survival of 6.3 months in patients with pretreated NSCLC and KRAS p.G12C mutations.
Research highlights barriers to lung cancer care for marginalized communities, including racial and ethnic minorities, LGBTQ+ individuals, and low-income patients. Key findings also show sex disparities in lung cancer incidence rates across countries.
The study identified 42 deleterious variants in 35 genes among patients with small cell lung cancer, including MLH1, BRCA2, and MUTYH germline mutations. These variants were associated with increased risk of first-degree relatives with cancer or lung cancer and longer recurrence-free survival following platinum-based chemotherapy.
A study in Journal of Thoracic Oncology found that routine thoracic surgery and invasive examinations were performed safely during the COVID-19 pandemic. The study analyzed data from a single Chinese hospital and showed that careful screening, patient protection, and effective medical staff precautions enabled safe operations.
Researchers at Princess Margaret Cancer Centre found that over 80% of advanced NSCLC patients had genomic alterations detected in cfDNA. Liquid biopsies were shown to be a timely and effective method for diagnosing and monitoring the disease, with actionable alterations detected in over 56% of treatment-naïve patients.
A pilot study comparing liquid biopsy with tissue-based test found that liquid biopsy results were approximately 10 days faster than tissue biopsy. Liquid biopsy identified actionable genes in 14 cases, while tissue biopsy only detected them in 11 cases.
A recent study found that combining aspirin, metformin, and statins may decrease lung cancer incidence and mortality. The research analyzed data from over 732,000 Koreans and discovered that concurrent use of these medications was associated with lower risk and mortality rates.
A study found that current USPSTF and CMS guidelines for lung cancer screening undercount African Americans due to their age, smoking history, and quitting time. The PLCOm2012 model improved sensitivity in both Whites and African American ever-smokers, eliminating the eligibility disparity.
The combination of first-line nivolumab and ipilimumab demonstrated an improvement in overall survival compared to platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma. The study showed a two-year overall survival rate of 40.8% for the treatment arm vs 27.0% for the chemotherapy arm.
The addition of sintilimab to pemetrexed and platinum chemotherapy significantly improved progression-free survival in patients with non-squamous non-small cell lung cancer, with a nearly two-fold increase observed. The overall response rate was also higher in the sintilimab-combination group compared to the placebo combination.
In a Phase 3 study, ensartinib demonstrated statistically significant longer progression-free survival compared to crizotinib in ALK+ NSCLC patients. The study found that ensartinib significantly prolonged overall response rate and time-to-treatment-failure rate in brain metastases
The International Association for the Study of Lung Cancer found that molecular testing rates for lung cancer are less than 50% in most countries. The most frequent barrier to testing was cost, followed by quality/standards and access.
A review of lung cancer treatments for patients with COVID-19 was published to assist oncologists in addressing the challenges presented by these patients. The guidelines balance risk of exposure and infection with effective care, taking into account existing comorbidities.
A recent study published in the Journal of Thoracic Oncology found that lung cancer clinical trials funded by the pharmaceutical industry demonstrate no more bias compared to studies funded by other sources. The analysis, led by Dr. Pedro Aguiar, assessed 477 studies and found that pharmaceutical-backed trials had stronger evidence, ev...
Including smoking cessation with existing lung cancer screening efforts would significantly reduce lung cancer mortality and increase life-years gained. The study found that point-of-screening cessation interventions could further reduce lung cancer deaths by 14% and increase life-years gained by 81%.
A study has described the pathology of SARS-CoV-2, or COVID-19, for the first time in its early phase. The research reveals edema, proteinaceous exudate, and inflammatory cellular infiltration in patients with COVID-19 pneumonina.
Recent advances in immunotherapy are starting to show hope for small cell lung cancer patients, but current treatments have limited durability and many patients don't respond. Researchers call for further exploration of underlying disease mechanisms and development of predictive biomarkers to advance the field.
A new study presented at the IASLC 2019 North America Conference on Lung Cancer found that lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders. Low-dose computed tomography was shown to detect disease earlier in this population.
A nurse-led follow-up service has improved patient care for those with early-stage lung cancer by increasing clinic capacity, reducing waiting times, and ensuring continuity of care. The service also promotes junior medical training and is well-received by patients and the multidisciplinary team.
The KEYNOTE-024 trial found that pembrolizumab significantly improved progression-free and overall survival in patients with advanced non-small-cell lung cancer. Patients treated with pembrolizumab had a median overall survival of 26.3 months compared to 14.2 months for those on chemotherapy.
The Impower131 Trial found that atezolizumab + chemotherapy improved overall survival by 3.9 months compared to chemotherapy alone, particularly among patients with high PD-L1 expression. Treatment-related side effects were common but manageable in both arms.
Patients taking nivolumab experience a significant five-fold increase in overall survival, with five-year rates of 13.4% compared to docetaxel's 2.6%. Long-term benefits and improved progression-free survival have been observed with nivolumab treatment.
A survey of European patients with lung cancer revealed that many were unaware of or had never heard of clinical trials. Despite positive experiences by over 50%, respondents identified difficulties in accessing trials, including language barriers, limited information, and disparities across Europe.
The bioMILD trial demonstrated that a blood microRNA assay, combined with low-dose CT screening, is safe and effective in enhancing lung cancer prevention. Preliminary analysis showed a significantly higher lung cancer incidence and overall mortality in subjects with positive LDCT and/or miRNA at baseline.
The LIBRETTO-001 trial showed that selpercatinib achieved high response rates of up to 68% in patients with RET fusion-positive non-small cell lung cancer. The median duration of response was also notable at 20.3 months, with an intracranial objective response rate of 91%.
The NLMT trial tests eight targeted therapies tailored to specific molecular changes in cancer cells. Researchers found promising responses with single-agent targeted therapy, particularly in oncogene-addicted NSCLC, and identified potential biomarkers for further research.
A new trial found that video-assisted thoracic surgery (VATS) significantly reduces in-hospital complications and shortens hospital stays compared to open surgery for early-stage lung cancer patients. VATS, a minimally invasive technique, showed improved outcomes without compromising oncologic results.
Durvalumab plus chemotherapy significantly improved overall survival in patients with extensive-stage small cell lung cancer, with a median survival of 13 months compared to 10.3 months for the control group. The study found that 33.9% of patients receiving durvalumab were alive at 18 months.
A Scottish study shows that combining an autoantibody test with CT imaging can significantly decrease late-stage lung cancer diagnoses and potentially lower lung cancer-specific mortality. The EarlyCDT-Lung Test identifies high-risk individuals, allowing for earlier interventions.
A European lung cancer screening model outperformed a US model in detecting cancers, with 99% of cancers found using the European method compared to 77%. The study found that the model detected more cancers among high-risk patients and had a higher accuracy rate.
A Phase 1 study demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation. The therapy, AMG 510, showed encouraging anti-tumor activity with no dose-limiting toxicities or adverse events leading to discontinuation.
The MYSTIC trial found that patients with STK11 or KEAP1 mutations had poorer outcomes to anti-PD-L1 and anti-CTLA-4 immunotherapies compared to those without these mutations. ARID1A mutations were associated with improved survival in the durvalumab + tremelimumab arm.
The MYSTIC trial found that patients with STK11 or KEAP1 gene mutations in metastatic non-small cell lung cancer experienced poorer overall survival compared to those without these mutations. Additionally, patients with ARID1A mutations in the durvalumab + tremelimumab arm had longer median overall survival rates.
Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...
Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.
The bioMILD trial demonstrated that combining low-dose CT screening with a microRNA blood test reduces lung cancer mortality and incidence in high-risk individuals. The study found that participants with positive LDCT and/or miRNA at baseline had a significantly higher lung cancer incidence and overall mortality.
Researchers found no significant correlation between tumor mutational burden and response rates, progression-free survival, or overall survival in patients treated with pembrolizumab plus carboplatin and pemetrexed. High objective response rates were observed in both TMB low and high subgroups.
Cancer patients who continue smoking after diagnosis have a higher mortality rate and increased risk for second cancer development. The IASLC Declaration recommends screening all cancer patients for tobacco use and advising on tobacco cessation.
A follow-up study reaffirms the effectiveness of low-dose computed tomography (LDCT) in reducing lung cancer mortality. The research found that LDCT can prevent lung cancer deaths or at least delay them for more than a decade, with only 303 patients needed to be screened to prevent one death.
The IASLC has launched a pilot project to develop an innovative technique for improving early lung cancer detection through shared computed tomography images. The project aims to create a globally-accessible environment for analyzing large collections of quality-controlled CT lung cancer images and associated biomedical data.
A study published in the Journal of Thoracic Oncology found that elderly patients with limited-stage small cell lung cancer (LS-SCLC) can benefit from concurrent chemo-radiotherapy, similar to younger patients. The analysis showed comparable survival rates and toxicity between older and younger groups, providing robust evidence for tre...
The IASLC affirms the strength of evidence supporting lung cancer screening, reducing mortality by 26-61% in high-risk populations. The organization recommends implementing global lung cancer screening programs, incorporating multidisciplinary teams and best-practice smoking cessation.
Patients with metastatic non-small cell lung cancer (NSCLC) treated at academic centers had higher 2-year survival rates than those treated at community-based centers. The study found significant differences in survival outcomes based on facility type, histology, and molecular profile.
A study published in the Journal of Thoracic Oncology found that active surveillance of lung subsolid nodules can reduce unnecessary surgery and overtreatment. Lung cancers arising from these nodules rarely led to death, suggesting they can be a biomarker for cancer risk.
The International Association for the Study of Lung Cancer (IASLC) has issued a statement paper on liquid biopsy for advanced non-small cell lung cancer, recommending its use for molecular analysis in guiding clinical management. The paper aims to provide general oncologists and clinicians with access to the latest information on liqui...
A study analyzed 154,498 NSCLC and 27,834 SCLC patients who died on or before December 31, 2013, revealing racial-ethnic disparities in end-of-life care quality. Minority patients had higher odds of preventable medical encounters, delayed hospice referral, and aggressive chemotherapy during end-of-life.
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
The updated guideline strengthens recommendations for patients with lung adenocarcinoma, recommending testing for ROS1 mutations and multiplexed genetic sequencing panels. The panel also reaffirmed or strengthened existing recommendations, including testing in relapse for EGFR T790M, with some notable changes.